Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MYRIAD GENETICS INCMYGN · Entity 5953 | Director | December 13, 2019 | December 16, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MYRIAD GENETICS INC
Report date December 13, 2019 · Filed December 16, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,150 |
Reported balance
After 2019-12-13 transaction · row 1
1 source rowRow 1 · 2019-12-13 · Purchase · Acquired 5,860 · Balance 54,150 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2019 Filed Dec 16, 2019 21:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | PurchaseCommon Stock | 5,860 | $25.60 | $149,997.83 |
DisclosureSEC source: 0001236368-19-000003 · edgardoc.xml · nonDerivative · entry 1 GILBERT WALTER PHD · CIK 0001236368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,150 Read SEC document |
| December 05, 2019 Filed Dec 6, 2019 18:25 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 11,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001379372-19-000004 · edgardoc.xml · nonDerivative · entry 1 GILBERT WALTER PHD · CIK 0001236368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,290 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
| November 29, 2018 Filed Nov 30, 2018 17:52 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 9,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001236368-18-000004 · edgardoc.xml · nonDerivative · entry 1 GILBERT WALTER PHD · CIK 0001236368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,603 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 20:00 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,189 | $0.00 Strike: $24.39 | $0.00 |
DisclosureSEC source: 0001236368-18-000002 · edgardoc.xml · derivative · entry 6 GILBERT WALTER PHD · CIK 0001236368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,189 shares Expires 2018-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 20:00 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 1,189 | $39.80 | $47,322.20 |
DisclosureSEC source: 0001236368-18-000002 · edgardoc.xml · nonDerivative · entry 4 GILBERT WALTER PHD · CIK 0001236368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,243 Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 20:00 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 1,189 | $24.39 | $28,999.71 |
DisclosureSEC source: 0001236368-18-000002 · edgardoc.xml · nonDerivative · entry 3 GILBERT WALTER PHD · CIK 0001236368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:00 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 28,811 | $0.00 Strike: $24.39 | $0.00 |
DisclosureSEC source: 0001236368-18-000002 · edgardoc.xml · derivative · entry 5 GILBERT WALTER PHD · CIK 0001236368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,189 Underlying: Common Stock · 28,811 shares Expires 2018-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:00 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 28,811 | $39.68 | $1,143,266.58 |
DisclosureSEC source: 0001236368-18-000002 · edgardoc.xml · nonDerivative · entry 2 GILBERT WALTER PHD · CIK 0001236368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,243 Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:00 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 28,811 | $24.39 | $702,700.29 |
DisclosureSEC source: 0001236368-18-000002 · edgardoc.xml · nonDerivative · entry 1 GILBERT WALTER PHD · CIK 0001236368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 20:09 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 7,500 | $33.19 | $248,925.00 |
DisclosureSEC source: 0001236368-17-000004 · edgardoc.xml · nonDerivative · entry 1 GILBERT WALTER PHD · CIK 0001236368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,243 Read SEC document |
| November 30, 2017 Filed Dec 1, 2017 00:26 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 7,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001236368-17-000002 · edgardoc.xml · nonDerivative · entry 1 GILBERT WALTER PHD · CIK 0001236368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,743 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 00:13 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 15,024 | $0.00 | $0.00 |
DisclosureSEC source: 0001236368-16-000006 · edgardoc.xml · nonDerivative · entry 1 GILBERT WALTER PHD · CIK 0001236368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,524 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2010 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.